CD20: A review

被引：0
|
作者：
Chang, KL
Arber, DA
Weiss, LM
机构：
来源：
APPLIED IMMUNOHISTOCHEMISTRY | 1996年 / 4卷 / 01期
关键词：
CD20; immunohistochemistry; mature B-cells; B-cell lymphoma; B-cell ontogeny; REED-STERNBERG CELLS; HUMAN LYMPHOCYTE-B; PARAFFIN SECTION IMMUNOHISTOCHEMISTRY; NON-HODGKINS LYMPHOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; MONOCLONAL-ANTIBODIES; BONE-MARROW; DIFFERENTIATION ANTIGEN; PREDOMINANCE TYPE; EPITHELIAL-CELLS;
D O I：
暂无
中图分类号：
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号：
100101 ;
摘要：
CD20 is a membrane-embedded 35-37 kDa nonglycosylated phosphoprotein that is a restricted B-cell antigen. CD20 antibodies are available for paraffin and frozen section immunohistochemistry and for flow cytometric analysis. Its clinical utility is greatest for identifying B-lineage non-Hodgkin's lymphomas, but it can also aid in the diagnosis of nodular lymphocyte predominance Hodgkin's disease and acute lymphoblastic neoplasms. CD20 immunotoxins have also been used experimentally to treat B-cell lymphomas that do not respond to conventional chemotherapy or radiation therapy.
引用
收藏
页码：1 / 15
页数：15
相关论文
共 50 条
  • [21] Development of human bispecific antibodies against CD20/CD55 or CD20/CD59 for the treatment of Burkitt lymphoma
    Macor, P.
    Secco, E.
    Mezzaroba, N.
    De Maso, L.
    Durigutto, P.
    Gaiotto, T.
    Garrovo, C.
    Biffi, F.
    Zorzet, S.
    Sblattero, D.
    Tedesco, F.
    MOLECULAR IMMUNOLOGY, 2010, 47 (13) : 2287 - 2287
  • [22] Targeting CD20 in multiple sclerosis-review of current treatment strategies
    Chmielewska, Natalia
    Szyndler, Janusz
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2023, 57 (03) : 235 - 242
  • [23] Measuring CD20 binding for humanization of anti-CD20 antibody
    Meng, YJG
    Hong, K
    Presta, L
    Penn, A
    Adams, C
    Chuntharapai, A
    Yang, JH
    Lu, YM
    Wong, WL
    FASEB JOURNAL, 2004, 18 (04): : A59 - A59
  • [24] The CD20/αCD20 ‘suicide’ system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells
    T van Meerten
    M-J Claessen
    A Hagenbeek
    S B Ebeling
    Gene Therapy, 2006, 13 : 789 - 797
  • [25] The CD20/αCD20 'suicide' system:: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells
    van Meerten, T
    Claessen, MJ
    Hagenbeek, A
    Ebeling, SB
    GENE THERAPY, 2006, 13 (09) : 789 - 797
  • [26] CD20 antibodies: doing the time warp
    Cragg, Mark S.
    BLOOD, 2011, 118 (02) : 219 - 220
  • [27] Rituximab in CD20 positive multiple myeloma
    J M Bergua
    C Cabrera
    E G Arteta
    J Prieto
    Leukemia, 2008, 22 : 1082 - 1083
  • [28] Rituximab in CD20 positive multiple myeloma
    P Moreau
    L Voillat
    L Benboukher
    C Mathiot
    C Dumontet
    N Robillard
    O Hérault
    F Garnache
    R Garand
    N Varoqueaux
    H Avet-Loiseau
    J L Harousseau
    R Bataille
    Leukemia, 2007, 21 : 835 - 836
  • [29] Response to: Monoclonal antibodies targeting CD20
    Klein, Christian
    Lammens, Alfred
    Schaefer, Wolfgang
    Georges, Guy
    Schwaiger, Manfred
    Moessner, Ekkehard
    Hopfner, Karl-Peter
    Umana, Pablo
    Niederfellner, Gerhard
    MABS, 2013, 5 (03) : 337 - 338
  • [30] Mice carrying a CD20 gene disruption
    Theresa L. O’Keefe
    Gareth T. Williams
    Sarah L. Davies
    Michael S. Neuberger
    Immunogenetics, 1998, 48 : 125 - 132
12345